Bardonnaud N, Pillot P, Lillaz J, Delorme G, Chabannes E, Bernardini S, Guichard G, Bittard H, Kleinclauss F
Department of Urology and Renal Transplantation, University Hospital Saint-Jacques, Besançon, France.
Transplant Proc. 2012 Nov;44(9):2787-91. doi: 10.1016/j.transproceed.2012.09.031.
Although obesity has been shown to paradoxically increase dialysis patient survival, its impact has not been clearly defined on renal transplantation. We assessed outcomes of obesity renal transplant patients by evaluating graft and patient survivals.
A single-institution, retrospective study was performed on 202 renal transplant recipients from January 2004 to December 2008 excluding two combined kidney and liver transplantations. Recipients were classified based on body mass index (BMI) at the time of transplantation: obese (BMI ≥ 30 kg/m(2)) and nonobese recipients (BMI < 30 kg/m(2)). The comparative analysis included surgical complications, hospital stay, onset of delayed graft function (DGF), acute rejection episodes and graft patient survivals.
Twenty-one renal transplants were performed in obese recipients versus 179 in the control group. Obese patients were older (53.3 ± 11.2 versus 46.4 ± 14.4 years old; P = .035) and more often diabetic (29% ± 0.46 versus 60% ± 0.24, P = .001), but there were no differences among other combidities of high blood pressure, arteriopathy, thrombophilia, and smoking. Obesity did not appear to be a risk factor for urinary or vascular as well as parietal complications, but did tend to augment lymphatic complications (14.3% ± 0.36 versus 4.5% ± 0.21; P = .065). DGF occurred more frequently in obese patients (38% ± 0.50 versus 14% ± 0.34; P = .004) and hospital stays were therefore longer in this group (24.9 ± 23.53 days versus 15.6 ± 13.67 days; P = .008). Graft (hazard ratio [HR] 1.22; 95% confidence interval [CI] [0.25-6.0], P = .63) and patient survivals (HR:0,81; 95% CI [0.12- 5.3], P = .83) were comparable between the groups.
Obese patients seeking renal transplantation are usually older and more often diabetic compared with nonobese recipients. The higher rate of lymphatic complications and DGF lead to longer hospital stays among the group with BMI ≥ 30 kg/m(2). However, long-term results showed similar graft and patient survivals as nonobese patients. Consequently, there seemed to be no reason to avoid renal transplantation in obese recipients.
尽管肥胖已被证明反常地提高了透析患者的生存率,但其对肾移植的影响尚未明确界定。我们通过评估移植物和患者的生存率来评估肥胖肾移植患者的预后。
对2004年1月至2008年12月间202例肾移植受者进行单中心回顾性研究,排除2例肝肾联合移植。根据移植时的体重指数(BMI)将受者分类:肥胖(BMI≥30kg/m²)和非肥胖受者(BMI<30kg/m²)。比较分析包括手术并发症、住院时间、移植肾功能延迟恢复(DGF)的发生、急性排斥反应发作以及移植物和患者的生存率。
肥胖受者进行了21例肾移植,而对照组为179例。肥胖患者年龄较大(53.3±11.2岁对46.4±14.4岁;P = 0.035)且糖尿病发生率更高(29%±0.46对60%±0.24,P = 0.001),但在高血压、动脉病、血栓形成倾向和吸烟等其他合并症方面无差异。肥胖似乎不是泌尿系统或血管以及腹壁并发症的危险因素,但确实倾向于增加淋巴并发症(14.3%±0.36对4.5%±0.21;P = 0.065)。肥胖患者中DGF更频繁发生(38%±0.50对14%±0.34;P = 0.004),因此该组住院时间更长(24.9±23.53天对15.6±13.67天;P = 0.008)。两组间移植物(风险比[HR]1.22;95%置信区间[CI][0.25 - 6.0],P = 0.63)和患者生存率(HR:0.81;95%CI[0.12 - 5.3],P = 0.83)相当。
与非肥胖受者相比,寻求肾移植的肥胖患者通常年龄较大且糖尿病发生率更高。BMI≥30kg/m²组中较高的淋巴并发症和DGF发生率导致住院时间更长。然而长期结果显示移植物和患者生存率与非肥胖患者相似。因此,似乎没有理由避免对肥胖受者进行肾移植。